metabolic dysfunction-associated steatotic liver disease
Conditions
Interventions
Observation group:none
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age = 18 years and < 80 years; 2. Have metabolic risk factors (obesity, type 2 diabetes, dyslipidemia, hypertension, etc.); 3.Have undergone FibroScan non-invasive assessment, which can provide liver stiffness (LSM) and liver fat content (CAP value) for baseline and follow-up analysis.
Exclusion criteria
Exclusion criteria: 1. Patients with other clear liver diseases during the baseline or follow-up period, including those with positive hepatitis B surface antigen, those with active hepatitis C infection that has not been cured, drug-induced liver injury, autoimmune liver disease, and hereditary liver disease, etc. 2.Patients with active viral infections, such as HIV infection or other active infections that may affect liver function and metabolism, to avoid confounding factors interfering with the analysis. 3.Patients with malignant tumors at baseline or within the previous five years are excluded to prevent the interference of tumors and related treatments on liver and metabolic status. 4. Pregnant or lactating women are excluded to avoid the influence of physiological conditions on liver lipid metabolism and fluid status. 5.Patients who have not completed key examinations or have missing key follow-up data are excluded, such as those lacking FibroScan, imaging or laboratory indicators, to ensure the completeness of the main evaluation indicators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The prevalence rate of MASLD; | — |
Secondary
| Measure | Time frame |
|---|---|
| Liver fibrosis and fat content;Liver-related events;metabolism-related complications; | — |
Countries
China
Contacts
Public ContactYu Shi
The first affiliated hospital, Zhejiang University School of Medicine
Outcome results
None listed